# Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)

> **NCT00452387** · PHASE2 · TERMINATED · sponsor: **Accelerated Community Oncology Research Network** · enrollment: 22 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Mitoxantrone
- **DRUG:** Prednisone
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT00452387
- **Lead sponsor:** Accelerated Community Oncology Research Network
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2008-07
- **Final completion:** 2009-01
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Early stopping rule
- **Last updated:** 2011-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00452387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00452387, "Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00452387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*